Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severity.

Brain : a journal of neurology·2026
Same author

Global overview of multiple sclerosis care units: an international cross-sectional survey.

Frontiers in neurology·2026
Same author

Motor tract lesion mapping from the brain to the lower spinal cord in people with relapsing-remitting multiple sclerosis: exploring the association between lesion severity and functional consequences by limb.

Brain communications·2026
Same author

Performances of experts and automated methods on new multiple sclerosis lesions detection: insights from the MSSeg2 challenge.

Scientific reports·2026
Same author

PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis.

JAMIA open·2026
Same author

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database.

Multiple sclerosis and related disorders·2026

Related Experiment Video

Updated: May 11, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Induction therapy for patients with multiple sclerosis: why? When? How?

Gilles Edan1, Emmanuelle Le Page

  • 1Department of Neurology, CIC-P 02-03 INSERM, INCR, CHU Pontchaillou, 35033, Rennes Cedex, France. gilles.edan@chu-rennes.fr

CNS Drugs
|May 10, 2013
PubMed
Summary

Induction therapy with mitoxantrone followed by maintenance treatment offers sustained disease control for aggressive multiple sclerosis (MS). This combination provides better outcomes than interferon beta monotherapy for managing MS activity.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

Related Experiment Videos

Last Updated: May 11, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) management often involves induction and maintenance therapy.
  • Aggressive MS requires effective treatment strategies to control disease activity and accumulation of lesions.
  • Combination therapy, particularly mitoxantrone induction followed by immunomodulatory maintenance, is of significant interest.

Purpose of the Study:

  • To evaluate the efficacy of induction-maintenance treatment strategies in multiple sclerosis.
  • To compare combination therapy with monotherapy for managing aggressive MS.
  • To assess the long-term disease control achieved with specific induction-maintenance regimens.

Main Methods:

  • Review of long-term studies and randomized trials on MS treatment.
  • Analysis of treatment protocols involving mitoxantrone induction followed by immunomodulatory drugs (interferon beta, glatiramer acetate).
  • Comparison of efficacy against interferon beta monotherapy and consideration of natalizumab and alemtuzumab treatments.

Main Results:

  • A 6-month course of mitoxantrone induction followed by maintenance therapy demonstrated rapid reduction in MS disease activity and sustained control for at least 5 years.
  • Randomized studies indicated that mitoxantrone induction followed by maintenance therapy provided superior disease control compared to interferon beta monotherapy.
  • Alemtuzumab showed long-term clinical benefits in early relapsing MS patients, despite risks of systemic autoimmune disease.

Conclusions:

  • The induction-maintenance approach, exemplified by mitoxantrone followed by immunomodulatory drugs, is effective for aggressive multiple sclerosis.
  • This strategy offers sustained disease control and is more effective than interferon beta monotherapy.
  • While effective, other agents like natalizumab and alemtuzumab have specific considerations regarding withdrawal and potential side effects.